They found that the expression level of receptor activator of NF-κB ligand (RANKL) was decreased to the basal level of the non-tumor bearing mouse, and the activation of osteoclastic cells was decreased after adding erlotinib. The gene discussed is TNFSF11; the disease is neoplasm.